39results about How to "Prolonged dosing time" patented technology

The invention relates to ivermectin sustained-release microspheres used as an animal medicine for animal injection, and a preparation method thereof. The invention belongs to an interdisciplinary field of biomedical polymer materials and controlled release preparations. The invention discloses ivermectin sustained-release microspheres, which are characterized in that: the ivermectin sustained-release microspheres have particle sizes of 0.1 to 10mum, a medicine loading capacity of 20% to 35%, and an entrapment rate of above 80%. The preparation method of the ivermectin sustained-release microspheres comprises steps that: a carrier material and the medicine ivermectin with a mass ratio of 1:1-10 are dissolved in an organic solvent; the solution is processed through supersonic wave or mechanical stirring, such that the solution is emulsified into an oil phase, wherein a volume ratio of oil phase to water phase is 1:5-10; under a temperature of -10 DEG C to 30 DEG C, the oil phase is injected into a water phase disperse medium solution step-by-step; constant-temperature magnetic stirring is carried out with a rotation speed of 400 to 10000rpm, the mixture is sufficiently emulsified, such that an S/O/W type emulsion is obtained; the emulsion is stirred under room temperature for 3 to 4 hours, such that the organic solvent is sufficiently volatilized; the obtained product is centrifuged, washed, collected, and is vacuum-dried with a pressure of 0.01 to 0.04MPa under room temperature for 10 to 12 hours or is lyophilized under a temperature of -0 DEG C to -20 DEG C. With the processes, ivermectin sustained-release microspheres with particle sizes of 0.1 to 10mum are obtained.

The invention discloses a propranolol hydrochloride lipidosome gel, which is prepared by the following bulk drugs and auxiliary materials by weight percent: 0.012-0.075% of propranolol hydrochloride, 0.037-0.150% of phosphatidyl ethanolamine, 0.012-0.075% of cholesterol, 2.5-5% of triethanolamine, 1-2% of carbopol, and the balance of water. According to the propranolol hydrochloride lipidosome gel, during the preparation, the lipidosome is uniformly dispersed in the gel, so that the stability of the lipidosome is improved; the water-soluble gel carbopol has excellent biocompatibility, can be well adhered to skin and cannot stimulate skin; drug administration time is prolonged, the toxic and side effects on the whole body are reduced, the adaptability of patients is improved, and the propranolol hydrochloride lipidosome gel has excellent application prospect.

The invention relates to methotrexate intralipid, a freeze-dried agent, a preparation method and an application thereof. The methotrexate intralipid consists of methotrexate active ingredient, oil for injection, emulsifying agent, stabilizing agent, isotonic adjustment agent, antioxidant, amylose, water for injection and pH modifying agent. The methotrexate intralipid of the invention is freeze-dried to obtain the freeze-dried agent of the methotrexate intralipid. The methotrexate intralipid and the freeze-dried agent of methotrexate intralipid can be applied to the medicines for treating a tumor and rheumatoid diseases.

The invention relates to an ethyl cellulose drug-loading nanofiber membrane and preparation method and application thereof. The components of the nanofiber membrane include ethyl cellulose and drug of which the mass ratio is 1:10 to 1:20. The preparation method includes the steps of: adding the drug to an ethyl cellulose (EC) solution, and stirring to disperse uniformly, thereby obtaining a spinning solution; and performing electrostatic spinning, and drying an obtained fibrous membrane, thereby obtaining an ethyl cellulose drug-loading nanofiber membrane. The preparation method provided by the invention is simple and feasible; and the prepared nanofiber membrane is a hydrophobic nanometer material having a drug slow-release function and can be used as a biomedical material.

The invention discloses a drug for relieving pain and eliminating tumor and a preparation method thereof. The active ingredients of the drug for relieving pain and eliminating tumor are realgar and ginger, the weight ratio of the realgar and the ginger is (1 to 3): (1 to 3); and the particle size of the realgar and the ginger is 60 to 500nm. The drug further comprises a carrier, and the weight ratio of the realgar, the ginger and the carrier is (1 to 3): (1 to 3): (4 to 10). The drug for relieving pain and eliminating tumor can be prepared into a cream for relieving pain and eliminating tumor after being added the carrier. The drug for relieving pain and eliminating tumor of the invention has insignificant toxicity and side effects, and the plasma-drug concentration is stable.

The invention discloses a medicament for treating insomnia and a preparation method and application thereof. The medicament for treating insomnia is composed of the following components in mass percent: 2-6% of jujuboside extract, 16-22% of poloxamer P407, 1-6% of poloxamer P188, 6-12% of PEG400, 0.01-0.03% of nipagin and balance of phosphate buffer solution, wherein the sum of the mass percents is 100%. The medicament for treating insomnia disclosed by the invention adopts a temperature-sensitive gel as a dosage form of jujuboside, thus after the medicament is dripped in liquid form into the nasal cavity, the medicament can flow onto mucous membrane in the deeper olfactory region where the brain bioavailability is verified high for administration; the medicament changes into semi-solid with a biological adhesion action in the nasal cavity, thereby continuously attaching to the mucous membrane in the olfactory region, solving the problem that the traditional dosage form is liable to lose and result in lower bioavailability and transient administration, and improving the sleeping quality of patients continuously.

The invention discloses an arbidol hydrochloride injection preparation. The injection preparation is prepared from an active ingredient arbidol hydrochloride, a pharmaceutically acceptable co-solventand a buffer solution. The invention further discloses a preparation method of the arbidol hydrochloride injection preparation. The preparation method comprises the following steps: adding the buffersolution and the co-solvent, performing uniform stirring, and slowly and uniformly adding arbidol hydrochloride into the mixture to sufficiently dissolve the arbidol hydrochloride in the mixture; adjusting the pH value of the mixture, adding activated carbon into the mixture, and performing uniform stirring; performing decarbonization, filtering filtrate through a microfiltration membrane, fillinga sterilized ampoule with the filtrate, and sealing the sterilized ampolue; and finally, performing water-bath sterilization. The arbidol hydrochloride injection preparation is applicable to intramuscular injection and is mainly used for preventing and treating type A and type B influenza and other acute respiratory virus infections. The injection preparation can be used for improving the bioavailability of the arbidol hydrochloride, prolonging the administration time, effectively reducing cross contamination, improving the stability of the injection preparation and facilitating clinical application.

The invention provides a cinnamyl aldehyde modified polyethylene glycol-polyamino acid block copolymer. The cinnamyl aldehyde modified polyethylene glycol-polyamino acid block copolymer comprises a first block with a structure as shown in a formula I or a formula II and a second block with a structure as shown in a formula III. On the basis of the traditional temperature-sensitive polyurethane hydrogel, the temperature-sensitive hydrogel formed by the block copolymer provided by the invention can be used for supporting an aldehyde micromolecular drug cinnamyl aldehyde from a natural source through a chemical bonding effect, regulating the bonding ratio of cinnamyl aldehyde, improving the solubility of cinnamyl aldehyde and prolonging the drug administration time through a sustained and controlled release effect, and the drug administration efficiency is increased. The drug-loaded temperature-sensitive hydrogel provided by the invention has temperature sensitivity and a drug loading effect at the same time, and can be singly used or combined with other drugs by utilizing the pharmacological action of cinnamyl aldehyde which is an aldehyde small molecular drug, so that the further application of the hydrogel is expanded.

The invention discloses application of all-cannabinoid in preparation of a drug for treating a Parkinson's disease (PD). The all-cannabinoid is prepared by uniformly mixing, by weight, 0.3-99.7 parts of an industrial hemp seed extract with 99.7-0.3 parts of industrial cannabinoids. Experiments prove that the prepared all-cannabinoid has the effects of removing free radicals, inhibiting lipid peroxidation and enabling generation and removal of oxygen radicals to be in dynamic balance to slow disease progress of the PD. The all-cannabinoid has a good application prospect on preparation of the drug for treating the Parkinson's disease.

Disclosed are improved methods for treating an infectious disease with yeast-based immunotherapy, including viral disease, such as disease resulting from hepatitis virus infection, using a pharmacogenomic and response-guided approach based on IL28B genotype of the individual.

The invention relates to a Chinese medicinal preparation, in particular to a Chinese medicinal patch for treating polycystic ovary syndrome and a preparation method thereof. The patch is prepared from the following components in part by weight: 20 to 40 parts of raw ark shell, 70 to 120 parts of white vinegar, 20 to 40 parts of Chinese angelica, 5 to 15 parts of cassia twig, 10 to 20 parts of nutgrass galingale rhizome (fried with vinegar), 10 to 30 parts of hiraute shiny bugleweed herb, 10 to 20 parts of red paeony root, 15 to 25 parts of raw white paeony root, 10 to 20 parts of liquoric root, 400 to 500 parts of sesame oil, 40 to 50 parts of beeswax and 4 to 8 parts of angelica oil. Animal experiments and clinical observation prove the curative effect of the patch, and prove that the effects of promoting blood circulation and removing blood stasis and eliminating dampness and dispelling phlegm of the patch are enhanced due to the compatibility of the medicines in a prescription.

The invention discloses a medicinal composition for regulating breath and nervous systems and application of the medicinal composition. The medicinal composition for regulating the breath and nervous systems comprises 100-500 parts of rhizoma atractylodis, 50-250 parts of Chinese violet, 100-500 parts of elecampane, 100-400 parts of folium artemisiae argyi and 20-80 parts of benzoin. The application refers to application of the medicinal composition for regulating the breath and nervous systems in preparing medicines for preventing/treating trachitis and rhinitis. By adopting the medicinal composition, the problems that lung discomfort can be caused as relatively large smoke can be generated because of poor sublimability of medicinal components of medicines for treating trachitis and rhinitis in the current market, and the medicines are complex in formula, high in price of formula materials and very low in cost performance, can be solved. According to the medicinal composition, a fumigant of medicines for treating trachitis and rhinitis is added into a matrix of an electric mosquito-repellent incense piece, when being used, a common electric mosquito-repellent incense box is opened, the mosquito-repellent incense piece with the fumigant of the medicines for treating trachitis and rhinitis is inserted into the common electric mosquito-repellent incense box, after the box is powered on, effective medicinal components can be volatilized into the air through electric heating, and thus the medicinal composition can be breathed in when people sleep.

The invention provides treatment equipment for improving the efficacy of traditional Chinese medicines to resist novel coronavirus. Modern medical research shows that the drug effect of nasal and lung administration is 16 times that of oral administration, which is proved by the appearance of atomized vaccines, traditional Chinese herbal medicine fumigation is nasal and lung administration, the difference between traditional Chinese herbal medicine fumigation and western medicine atomized administration is hot body perspiration and detoxification and drug efficacy strengthening and synergy, the drug efficacy can reach the deep part of a human body, pestilence is known as the cold-dampness epidemic cold category in traditional Chinese medicine, a method for coping with cold-dampness diseases is characterized in that heat is used for overcoming cold, the problem is that herbal medicine fumigation obstacles are that steam is difficult to tolerate, so that the administration time is restricted, and the treatment equipment disclosed by the invention is an extension innovation of the original invention patent CN201510111310.5, low-temperature herbal fumigation device, which can greatly improve the efficacy and solve the problem that oral traditional Chinese medicine can not treat severe diseases.